This Chronic Therapy Stock Rises 158% in 3 Years: Is the Big Merger Bet Paying Off?
- September 10, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
CMP around Rs 4,930 (10 Sep 2026). 3-year return 157.55%. 52W range Rs 3,480.60 to Rs 5,250. Market cap Rs 1,87,594 Cr. Q1 FY27 revenue Rs 4,921 Cr, up 55%.
Quick Answer
Torrent Pharma, a maker of heart, diabetes and gut medicines, is the chronic therapy stock behind a return of approximately 158% in three years. The share climbed from around Rs 1,914 to near Rs 4,930 on steady profit growth, 30%-plus margins and the JB Chemicals acquisition, which lifted Q1 FY27 revenue 55%. Valuations are rich at a PE near 87, and the share already trades near most brokerage targets.
This chronic therapy stock has turned Rs 1 lakh into roughly Rs 2.58 lakh over the past three years. One Ahmedabad-based drug maker delivered a 3-year return of 157.55% as of 10 September 2026, ranking 28th in a screen of 101 large-cap and mid-cap NSE shares.
The company is Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM), a maker of prescription medicines for heart, diabetes, gut and nervous system conditions. The Torrent Pharma share price has moved from approximately Rs 1,914 three years ago to around Rs 4,930 on 10 September 2026, and the company is now valued at approximately Rs 1,87,594 crore after absorbing JB Chemicals and Pharmaceuticals.
Click Here – Get Free Investment Predictions
Which Chronic Therapy Stock Rose 158% in 3 Years?
Torrent Pharma is the chronic therapy stock that rose approximately 158% in three years, ranking 28th out of 101 NSE stocks on the 3-year return table. The share closed at around Rs 4,930 on 10 September 2026, against a 52-week range of Rs 3,480.60 to Rs 5,250.
The rally in this chronic therapy stock was not a single spike. It was built in two phases: steady earnings growth from FY24 to FY26, followed by a re-rating tied to the JB Chemicals deal and new launches in 2026. Here is how this chronic therapy stock has performed across time frames:
| Period | Return (%) | Rank (out of 101) |
|---|---|---|
| 1 Month | 2.04% | 66 |
| 6 Months | 16.02% | 69 |
| 1 Year | 37.74% | 43 |
| 3 Years | 157.55% | 28 |
| 5 Years | 222.80% | 32 |
Returns are simple price changes and are not annualised. The 1-year gain of 37.74% is solid, but the 1-month return of only 2.04% shows momentum has cooled after the stock touched Rs 5,250. There was no stock split or bonus issue in the chronic therapy stock during the three-year window, and the face value stayed at Rs 5, so the 157.55% reflects real price appreciation.
Why Did This Chronic Therapy Stock Rise 158% in 3 Years?
This chronic therapy stock rose because four things came together: steady growth in its India prescription business, a return to growth in the US, consistent margin expansion and the JB Chemicals acquisition that nearly doubled its domestic scale. Each driver played out at a different stage of the three years.
1. Steady Earnings Growth From FY23 to FY26
The company behind this chronic therapy stock grew revenue from approximately Rs 9,665 crore in FY23 to around Rs 13,886 crore in FY26. Net profit rose from about Rs 1,245 crore to roughly Rs 2,138 crore over the same period, an increase of approximately 72%.
Operating margins stayed above 30% from FY22 to FY25, which is high for Indian pharma. Patients on long-term medicines for blood pressure, diabetes or heart conditions refill prescriptions for years, and that repeat demand is what makes a chronic therapy stock deliver steady cash flows.
2. The JB Chemicals Acquisition
The biggest trigger of the recent leg in the chronic therapy stock was the JB Chemicals deal, announced on 29 June 2025. Torrent Pharma agreed to buy a 46.39% stake in JB Chemicals and Pharmaceuticals from Tau Investment Holdings, an affiliate of KKR, for approximately Rs 11,917 crore, or Rs 1,600 per share.
The deal also triggered a mandatory open offer for another 26% at Rs 1,639.18 per share. By February 2026 Torrent held 48.80% of JB Chemicals on a fully diluted basis, and the merger of JB Chemicals into Torrent Pharma was then carried out through a share swap of 51 Torrent shares for every 100 JB Chemicals shares.
The National Company Law Tribunal, Ahmedabad Bench, sanctioned the scheme on 6 July 2026, and it became effective on 8 July 2026. On 20 July 2026 the company allotted 4,19,22,416 new shares to former JB Chemicals shareholders, lifting its total share count to 38,03,67,856.
For the chronic therapy stock, the deal adds well-known cardiac brands such as Cilacar and a contract manufacturing arm. It makes Torrent one of the larger players in the Indian cardiac market, a segment where doctors rarely switch patients once a therapy is working.
3. Semaglutide Launch in India
After the semaglutide patent expired in India in early 2026, several companies launched generic versions of the weight-loss and diabetes drug. The chronic therapy stock got a boost when Torrent Pharma launched both oral and injectable formulations and quickly emerged as the early leader.
Industry data for April 2026 showed Torrent held nearly 38% of the overall semaglutide segment, with monthly sales of approximately Rs 17 crore. Diabetes and obesity are long-duration conditions, the core market of any chronic therapy stock, so this launch fits neatly into the chronic therapy stock story and gives the company a new growth lever for FY27.
4. US Business Back to Growth
The US business of this chronic therapy stock had been weak for about five years because of regulatory issues and pricing pressure. In FY26 it turned around, helped by the launch of a generic version of the heart failure drug Entresto, and posted constant-currency growth of 21% in Q2 FY26.
In Q1 FY27 US revenue rose 36% to Rs 418 crore. A healthier US unit reduces the chance of a drag on consolidated growth, which had held back this chronic therapy stock in earlier years.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Chronic Therapy Stock Q1 FY27 Results: Revenue Up 55%
Torrent Pharma reported Q1 FY27 revenue of approximately Rs 4,921 crore on 30 July 2026, up 55% year on year, largely because JB Chemicals is now part of the consolidated numbers. Operating EBITDA rose 61% to Rs 1,664 crore, and the EBITDA margin improved to 33.8%.
Net profit rose only 3% to Rs 566 crore. For the chronic therapy stock, higher finance costs and depreciation linked to the acquisition, plus Rs 21 crore of exceptional items, including a Rs 19 crore inventory write-off after a warehouse fire at an erstwhile JB Chemicals site, absorbed most of the operating gain.
| Quarter | Revenue (Rs Cr) | EBITDA (Rs Cr) | Operating Margin | Net Profit (Rs Cr) |
|---|---|---|---|---|
| Jun 2025 | 3,141 | 995 | 31.81% | 548 |
| Sep 2025 | 3,275 | 1,056 | 32.13% | 591 |
| Dec 2025 | 3,290 | 1,075 | 32.76% | 635 |
| Mar 2026 | 4,180 | 1,339 | 30.84% | 364 |
| Jun 2026 | 4,909 | 1,652 | 33.73% | 566 |
Quarterly figures in the table include other income, so they differ slightly from the reported revenue from operations. The March 2026 quarter shows the first impact of consolidating JB Chemicals, with revenue jumping but profit dipping as acquisition costs came through.
Underneath the merger, the base business of this chronic therapy stock is doing well. Base business revenue grew 17% to Rs 3,720 crore with a 33.3% EBITDA margin, while the JB business grew 10% to Rs 1,201 crore at a 35.3% margin. India revenue rose 19% to Rs 2,157 crore, which management called record organic growth. Brazil grew 27% in rupee terms to Rs 277 crore, and Germany grew 3% to Rs 318 crore.
How Shareholding in the Chronic Therapy Stock Changed After the Merger
Promoter holding in this chronic therapy stock fell from 68.31% in June 2026 to 60.78% in July 2026. The drop is not a promoter sale. It is the arithmetic effect of 4.19 crore new shares being issued to former JB Chemicals shareholders under the swap ratio.
| Shareholder | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|
| Promoters | 68.31% | 68.31% | 68.31% | 68.31% | 60.78% |
| FIIs | 15.92% | 16.13% | 16.18% | 15.44% | 17.97% |
| DIIs | 9.28% | 9.14% | 9.06% | 9.83% | 12.87% |
| Public | 6.49% | 6.42% | 6.45% | 6.43% | 8.38% |
Foreign institutional holding rose to 17.97% and domestic institutional holding climbed to 12.87%, as institutions that owned JB Chemicals became Torrent shareholders. A wider institutional base improves liquidity in the chronic therapy stock and could raise its weight in index funds over time.
Key Risks Before Buying This Chronic Therapy Stock
The biggest risk for this chronic therapy stock is valuation. Torrent Pharma trades at a PE of approximately 87 against an industry PE of around 38, and at a price to book of about 22, so the market is already pricing in several years of merger synergies.
Higher debt: The acquisition was funded largely with borrowing. Debt to equity rose from 0.50 in FY25 to approximately 1.14 in FY26, and management aims to bring net debt to operating profit down to around 1.0x to 1.1x by FY28. Any slip in that plan would keep pressure on net profit.
Integration risk: For a chronic therapy stock, merging two sales forces, product lists and plants is complex. Q1 FY27 profit rose only 3% despite 55% revenue growth, which shows how much acquisition costs can weigh on earnings in the near term.
Price controls and competition: Many cardiac and diabetes drugs in India fall under price regulation, which caps pricing power. The semaglutide market is also crowded, with more than ten companies competing, so the early lead could narrow as prices fall.
Overseas exposure: Germany declined 9% in constant currency in Q1 FY27, and the US business depends on a limited number of key launches. A chronic therapy stock with international operations still faces currency and regulatory swings.
Download the Univest iOS App or Univest Android App to track the Torrent Pharma share price live
Torrent Pharma Share: Analyst View
The analyst view on the Torrent Pharma share, a leading chronic therapy stock, is broadly positive, with most coverage built around the JB Chemicals synergies. Analysts expect the combined India business to benefit from a larger field force, cross-selling of cardiac brands and cost savings in manufacturing.
After the Q2 FY26 results, one domestic brokerage projected revenue growth of about 14% a year and net profit growth of about 25% a year between FY25 and FY28. Analysts tracking this chronic therapy stock now watch three things: the pace of debt reduction, margin progress in the JB business and the scale-up of semaglutide sales.
Torrent Pharma Share Price Target
The most recent verified Torrent Pharma share price target is Rs 5,100, set by a domestic brokerage with a buy rating in May 2026. Against the Torrent Pharma share price of approximately Rs 4,930 on 10 September 2026, that implies upside of only about 3%.
The average consensus Torrent Pharma share price target was approximately Rs 4,879 in June 2026, which is already below the current market price. That suggests the chronic therapy stock has run ahead of most published estimates, and fresh upgrades would likely need stronger earnings after the merger.
On the chart, the 52-week high of Rs 5,250 is the level the Torrent Pharma share price needs to reclaim for the uptrend to resume. The 52-week low of Rs 3,480.60 marks the broader support zone. Any brokerage target for this chronic therapy stock is an estimate based on assumptions, not a guaranteed outcome.
Conclusion
Torrent Pharma earned its 158% three-year gain through steady earnings, high margins and a bold acquisition. Net profit grew from about Rs 1,245 crore in FY23 to Rs 2,138 crore in FY26, and the JB Chemicals merger has made this chronic therapy stock a much larger domestic player.
The trade-off is a PE near 87, higher debt and a share price that already sits above most analyst targets. Existing holders of this chronic therapy stock can track debt reduction and quarterly margins closely, while new investors may prefer staggered entries rather than chasing the Torrent Pharma share price near its highs.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which chronic therapy stock rose 158% in 3 years?
Ans. Torrent Pharmaceuticals (NSE: TORNTPHARM) is the chronic therapy stock that gained approximately 157.55% over three years as of 10 September 2026. It ranked 28th out of 101 large-cap and mid-cap NSE stocks on 3-year returns.
Why did the Torrent Pharma share price rise?
Ans. The Torrent Pharma share price rose on steady profit growth from FY23 to FY26, margins above 30%, a US business turnaround and the JB Chemicals acquisition. The launch of generic semaglutide in 2026 added a fresh growth driver.
What are the details of the JB Chemicals acquisition?
Ans. Torrent Pharma bought a 46.39% stake in JB Chemicals from a KKR affiliate for approximately Rs 11,917 crore at Rs 1,600 per share, announced on 29 June 2025. JB Chemicals was later merged into Torrent at 51 Torrent shares for every 100 JB shares, effective 8 July 2026.
What were Torrent Pharma Q1 FY27 results?
Ans. Torrent Pharma reported Q1 FY27 revenue of approximately Rs 4,921 crore, up 55%, and operating EBITDA of Rs 1,664 crore at a 33.8% margin. Net profit rose only 3% to Rs 566 crore because of acquisition-related finance costs, depreciation and exceptional items.
Why did promoter holding in Torrent Pharma fall?
Ans. Promoter holding fell from 68.31% to 60.78% in July 2026 because 4.19 crore new shares were issued to former JB Chemicals shareholders. The promoters did not sell shares; their stake was diluted by the merger.
Is this chronic therapy stock overvalued?
Ans. The chronic therapy stock trades at a PE of approximately 87 against an industry PE of about 38, which is a steep premium. The valuation assumes smooth merger synergies and debt reduction, so any delay could weigh on the share.
What is the Torrent Pharma share price target?
Ans. The latest verified Torrent Pharma share price target is Rs 5,100 from a domestic brokerage, set in May 2026. That implies upside of about 3% from around Rs 4,930, and the June 2026 consensus of approximately Rs 4,879 is below the current price.
Should I buy a chronic therapy stock after a 158% rally?
Ans. A 158% three-year rally means much of the good news is priced in, so fresh buyers face valuation and debt risk. Staggered buying, tracking quarterly margins and consulting a SEBI-registered advisor are sensible steps.
